Study Warns US Drug Policies Could Cost Swiss Pharmaceutical Sector Billions
A new industry-backed analysis is raising concerns about the long-term consequences of evolving US pharmaceutical trade and pricing policies, warning that Switzerland’s globally significant life sciences sector could face tens of billions of francs in economic losses over the coming decades. The report, commissioned by the Swiss pharmaceutical industry and released amid growing uncertainty surrounding…